NCT02322021 is a Phase 2 clinical trial of E2609 in Alzheimer Disease, sponsored by Eisai Inc..

Who is sponsoring NCT02322021?

NCT02322021 is sponsored by Eisai Inc..

What drugs are being tested in NCT02322021?

Interventions in NCT02322021: E2609, Placebo.

What condition does NCT02322021 study?

NCT02322021 studies Alzheimer Disease, Dementia, Alzheimer Type.

Is NCT02322021 still recruiting?

NCT02322021 is currently terminated. Last updated 5 March 2021.

Are results published for NCT02322021?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-05 · How we verify

NCT02322021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Terminated Phase 2 Results posted Last updated 5 March 2021

What this trial tests

Phase 2 trial testing E2609 in Alzheimer Disease in 70 participants. Terminated before completion.

Timeline

26 November 2014

Primary endpoint
20 December 2019

20 December 2019

Quick facts

Lead sponsor	Eisai Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	70
Start date	26 November 2014
Primary completion	20 December 2019
Estimated completion	20 December 2019
Sites	21 locations across United States

Drugs / interventions tested

E2609 — full drug profile →
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Dementia, Alzheimer Type — all drugs for Dementia, Alzheimer Type →

Sponsor

Eisai Inc. — full company profile →

Who can join

Adults 50 to 85, any sex, with Alzheimer Disease or Dementia, Alzheimer Type. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Core Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Primary · Up to 21 months

A TEAE is defined as an adverse event that emerges during treatment, having been absent at pre-treatment (Baseline) or re-emerges during treatment, having been present at pre-treatment (Baseline) but stopped before treatment, or worsens in severity during treatment relative to the pre-treatment state, when the adverse event is continuous.

Group	Value	95% CI
Core Phase: Placebo	15
Core Phase: Elenbecestat 5 mg Then 50 mg	15
Core Phase: Elenbecestat 15 mg Then 50 mg	18
Core Phase: Elenbecestat 50 mg	15

Core Phase: Number of Participants With Serious Adverse Events (SAEs) Primary · Up to 21 months

A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening (that is, the participant is at immediate risk of death from the adverse event as it occurs, this does not include an event that, has it occurred in a more severe form or is allowed to continue, might have cause death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect (in the child of a participant who is exposed to the study drug).

Group	Value	95% CI
Core Phase: Placebo	2
Core Phase: Elenbecestat 5 mg Then 50 mg	2
Core Phase: Elenbecestat 15 mg Then 50 mg	5
Core Phase: Elenbecestat 50 mg	1

Core Phase: Number of Participants With Treatment Emergent Markedly Abnormal Laboratory Safety Test Values Primary · Up to 21 months

Markedly Abnormal Low: Lymphocytes

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	2
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Leukocytes

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Neutrophils

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	1

Markedly Abnormal Low: Hemoglobin

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Calcium

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Potassium

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	1
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal High: Potassium

Group	Value	95% CI
Core Phase: Placebo	2
Core Phase: Elenbecestat 5 mg Then 50 mg	4
Core Phase: Elenbecestat 15 mg Then 50 mg	2
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal High: Alkaline Phosphatase

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	1

Core Phase: Number of Participants With Markedly Abnormal Vital Sign Values Primary · Month 0(Baseline,Week 2,Week 3,Week 4);Month 1(Week 5,Week 7);Month 2(Week 9,Week 11);Month 3(Week 13);Month 4(Week 17);Month 5(Week 21);Month 6(Week 27);Month 9(Week 40);Month 12(Week 53);Month 15(Week 66);Month 18(Week 79) and Follow-up at Month 1 and 3

Participants having no markedly abnormal vital sign values (no markedly abnormal high or no markedly abnormal low) in all core phase arms were not included in the data reported.

Markedly Abnormal Low: Temperature (Month 0: Baseline)

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	2
Core Phase: Elenbecestat 15 mg Then 50 mg	0
Core Phase: Elenbecestat 50 mg	2

Markedly Abnormal Low: Temperature (Month 0: Week 2)

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	2
Core Phase: Elenbecestat 50 mg	2

Markedly Abnormal Low: Temperature (Month 0: Week 3)

Group	Value	95% CI
Core Phase: Placebo	2
Core Phase: Elenbecestat 5 mg Then 50 mg	1
Core Phase: Elenbecestat 15 mg Then 50 mg	4
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Temperature (Month 0: Week 4)

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	3
Core Phase: Elenbecestat 15 mg Then 50 mg	1
Core Phase: Elenbecestat 50 mg	1

Markedly Abnormal High: Temperature (Month 0: Week 4)

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	1
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Temperature (Month 1: Week 5)

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	2
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Temperature (Month 1: Week 7)

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	1
Core Phase: Elenbecestat 15 mg Then 50 mg	3
Core Phase: Elenbecestat 50 mg	0

Markedly Abnormal Low: Temperature (Month 2: Week 9)

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	1
Core Phase: Elenbecestat 15 mg Then 50 mg	1
Core Phase: Elenbecestat 50 mg	2

Core Phase: Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Primary · Up to 21 months

QTcF interval means corrected QT interval (QTc) calculated using Fridericia's formula.

At least one post-baseline increase of >30 millisecond (msec) in QTcF interval

Group	Value	95% CI
Core Phase: Placebo	2
Core Phase: Elenbecestat 5 mg Then 50 mg	4
Core Phase: Elenbecestat 15 mg Then 50 mg	4
Core Phase: Elenbecestat 50 mg	2

At least one post-baseline value of >450 msec in QTcF interval

Group	Value	95% CI
Core Phase: Placebo	1
Core Phase: Elenbecestat 5 mg Then 50 mg	6
Core Phase: Elenbecestat 15 mg Then 50 mg	4
Core Phase: Elenbecestat 50 mg	3

At least one post-baseline value of >480 msec in QTcF interval

Group	Value	95% CI
Core Phase: Placebo	0
Core Phase: Elenbecestat 5 mg Then 50 mg	0
Core Phase: Elenbecestat 15 mg Then 50 mg	1
Core Phase: Elenbecestat 50 mg	0

Extension Phase: Number of Participants With TEAEs and SAEs Primary · Up to 34 months

TEAE: adverse event that emerges during treatment, having been absent at pre-treatment or reemerges during treatment, having been present at pre-treatment but stopped before treatment, or worsens in severity during treatment relative to pre-treatment state. Number of participants with TEAEs were reported based on safety assessments of laboratory tests, physical examination, regular measurement of vital signs, magnetic resonance imaging and electrocardiogram parameter values. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening (immediate risk of death fr

TEAEs

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	30

SAEs

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	6

Extension Phase: Number of Participants With Markedly Abnormal Vital Sign Values Primary · Up to 34 months

Markedly Abnormal High: Diastolic Blood Pressure

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Markedly Abnormal Low: Diastolic Blood Pressure

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Markedly Abnormal High: Systolic Blood Pressure

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	5

Markedly Abnormal High: Temperature

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Markedly Abnormal Low: Temperature

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	10

Markedly Abnormal High: Weight

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Extension Phase: Number of Participants With Markedly Abnormal ECG Findings Primary · Up to 34 months

QTcF interval means QTc interval calculated using Fridericia's formula.

At least one post-baseline increase of >30 msec in QTcF interval

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	2

At least one post-baseline value of >450 msec in QTcF interval

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	4

Extension Phase: Number of Participants With Treatment Emergent Markedly Abnormal Laboratory Safety Test Values Primary · Up to 34 months

Markedly Abnormal Low: Lymphocytes

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	4

Markedly Abnormal Low: Neutrophils

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	2

Markedly Abnormal Low: Hemoglobin

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Markedly Abnormal High: Potassium

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	4

Markedly Abnormal High: Alanine Aminotransferase

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Markedly Abnormal High: Gamma Glutamyl Transferase

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	2

Markedly Abnormal High: Glucose

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	3

Markedly Abnormal High: Triglycerides

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	2

Extension Phase: Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) Findings Primary · Up to 34 months

Brain MRIs are collected to assess for potential drug-related changes that might have constituted a safety concern. Safety brain MRI is assessed using a standardized procedure that included fluid-attenuated inversion recovery (FLAIR), gradient-echo, T1, and diffusion-weighted sequences to determine the presence of focal lesions including, but not limited to, evidence for ischemic and hemorrhagic stroke, subdural hematoma, neoplasm, arteriovenous malformation, micro and macrohemorrhages, superficial siderosis, lacunar infarcts, white matter abnormalities, and vasogenic edema. Participants with

Brain Vasogenic Edema

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	0

Brain Microhemorrhages

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	4

Brain White Matter Disease: Focal Lesions

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	25

Brain White Matter Disease: No Lesions

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	2

Area of superficial siderosis

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Space occupying lesion (extra axial): Meningioma

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Other pituitary lesion

Group	Value	95% CI
Extension Phase: Elenbecestat 50 mg	1

Core Phase: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid (A) Beta(1-x) and Abeta(1-42) After 1 Month and 18 Months of Treatment Secondary · Month 1 (Week 5) and Month 18 (Week 79)

The measurement of the amyloid proteins Abeta(1-x) and Abeta(1-42), in CSF have been shown to be important biomarkers for alzheimer's disease.

Percent Change from Baseline in CSF Abeta(1-x) at Month 1 (Week 5)

Group	Value	95% CI
Core Phase: Placebo	6.63	± 12.545
Core Phase: Elenbecestat 5 mg Then 50 mg	-18.16	± 17.873
Core Phase: Elenbecestat 15 mg Then 50 mg	-36.43	± 16.026
Core Phase: Elenbecestat 50 mg	-56.66	± 14.431

Percent Change from Baseline in CSF Abeta(1-x) at Month 18 (Week 79)

Group	Value	95% CI
Core Phase: Placebo	-1.81	± NA
Core Phase: Elenbecestat 5 mg Then 50 mg	-33.86	± 11.039
Core Phase: Elenbecestat 15 mg Then 50 mg	-0.71	± NA
Core Phase: Elenbecestat 50 mg	33.98	± 160.017

Percent Change from Baseline in CSF Abeta(1-42) at Month 1 (Week 5)

Group	Value	95% CI
Core Phase: Placebo	-8.53	± 16.818
Core Phase: Elenbecestat 5 mg Then 50 mg	-9.43	± 22.798
Core Phase: Elenbecestat 15 mg Then 50 mg	-20.69	± 15.488
Core Phase: Elenbecestat 50 mg	-38.89	± 16.378

Percent Change from Baseline in CSF Abeta(1-42) at Month 18 (Week 79)

Group	Value	95% CI
Core Phase: Placebo	-6.50	± 24.809
Core Phase: Elenbecestat 5 mg Then 50 mg	-27.19	± 20.172
Core Phase: Elenbecestat 15 mg Then 50 mg	-24.02	± 19.949
Core Phase: Elenbecestat 50 mg	-56.77	± 5.312

Core Phase: Mean Concentration of Elenbecestat in CSF Secondary · Month 1 (Week 5) and Month 18 (Week 79)

Month 1 (Week 5)

Group	Value	95% CI
Core Phase: Elenbecestat 5 mg Then 50 mg	1.10	± 0.438
Core Phase: Elenbecestat 15 mg Then 50 mg	3.71	± 1.360
Core Phase: Elenbecestat 50 mg	9.93	± 3.568

Month 18 (Week 79)

Group	Value	95% CI
Core Phase: Elenbecestat 5 mg Then 50 mg	0.10	± 0
Core Phase: Elenbecestat 15 mg Then 50 mg	2.72	± 3.197
Core Phase: Elenbecestat 50 mg	14.46	± 3.411

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 55 months (Core Phase: Up to 21 months; Extension Phase: Up to 34 months). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Core Phase: Placebo

Serious: 2/17 (12%)

Deaths: 0/17

Core Phase: Elenbecestat 5 mg Then 50 mg

Serious: 2/17 (12%)

Deaths: 0/17

Core Phase: Elenbecestat 15 mg Then 50 mg

Serious: 5/19 (26%)

Deaths: 0/19

Core Phase: Elenbecestat 50 mg

Serious: 1/17 (6%)

Deaths: 0/17

Extension Phase: Elenbecestat 50 mg

Serious: 6/41 (15%)

Deaths: 1/41

Serious adverse events (24 terms)

Reaction	System	Core Phase: Placebo	Core Phase: Elenbecestat 5…	Core Phase: Elenbecestat 1…	Core Phase: Elenbecestat 5…	Extension Phase: Elenbeces…
Appendicitis	Infections and infestations	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—
Localised infection	Infections and infestations	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—
Major depression	Psychiatric disorders	—	—	—	—	—
Affective disorder	Infections and infestations	—	—	—	—	—
Agitation	Psychiatric disorders	—	—	—	—	—
Neuropsychiatric symptoms	Psychiatric disorders	—	—	—	—	—
Angina pectoris	Cardiac disorders	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—
Rib fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Spinal column stenosis	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Delusion	Psychiatric disorders	—	—	—	—	—
Meningoencephalitis viral	Infections and infestations	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—
Pneumonia viral	Infections and infestations	—	—	—	—	—
Dementia Alzheimer's type	Nervous system disorders	—	—	—	—	—
Encephalopathy	Nervous system disorders	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—
Delirium	Psychiatric disorders	—	—	—	—	—
Diverticulum Intestinal Haemorrhagic	Gastrointestinal disorders	—	—	—	—	—
Wound Infection	Infections and infestations	—	—	—	—	—

Other adverse events (244 terms — click to expand)

Reaction	System	Core Phase: Placebo	Core Phase: Elenbecestat 5…	Core Phase: Elenbecestat 1…	Core Phase: Elenbecestat 5…	Extension Phase: Elenbeces…
Agitation	Psychiatric disorders	—	—	—	—	—
Upper Respiratory Tract Infection	Infections and infestations	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Urinary Tract Infection	Infections and infestations	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Abnormal Dreams	Psychiatric disorders	—	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Dermatitis Contact	Skin and subcutaneous tissue disorders	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Oedema Peripheral	General disorders	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—
Arthropod Bite	Injury, poisoning and procedural complications	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—
Laceration	Injury, poisoning and procedural complications	—	—	—	—	—
Ligament Sprain	Injury, poisoning and procedural complications	—	—	—	—	—
B-Lymphocyte Count Decreased	Investigations	—	—	—	—	—
Cd8 Lymphocytes Decreased	Investigations	—	—	—	—	—
Olfactory Test Abnormal	Investigations	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Pain In Extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Basal Cell Carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Decreased Vibratory Sense	Nervous system disorders	—	—	—	—	—
Depressed Mood	Psychiatric disorders	—	—	—	—	—
Nightmare	Psychiatric disorders	—	—	—	—	—
Dermatitis	Skin and subcutaneous tissue disorders	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—
Hand Fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Meniscus Injury	Injury, poisoning and procedural complications	—	—	—	—	—
Balance Disorder	Nervous system disorders	—	—	—	—	—
Sleep Apnoea Syndrome	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—
Atrioventricular Block Second Degree	Cardiac disorders	—	—	—	—	—

Most-reported serious reactions: Appendicitis, Influenza, Cellulitis, Localised infection, Syncope, Major depression, Affective disorder, Agitation.

Data from ClinicalTrials.gov NCT02322021 adverse events section.

Sponsor's own description

This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to Alzheimer's Disease (referred to as mild to moderate AD). This study will have a Core Phase and an Extension Phase.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Alzheimer's disease drug development pipeline: 2018.
Cummings J, Lee G, Ritter A, Zhong K. · · 2018 · cited 402× · PMID 29955663 · DOI 10.1016/j.trci.2018.03.009
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050
Alzheimer's disease drug development pipeline: 2017.
Cummings J, Lee G, Mortsdorf T, Ritter A, et al · · 2017 · cited 258× · PMID 29067343 · DOI 10.1016/j.trci.2017.05.002
The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.
Ricciarelli R, Fedele E. · · 2017 · cited 246× · PMID 28093977 · DOI 10.2174/1570159x15666170116143743
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
Das B, Yan R. · · 2019 · cited 142× · PMID 30830576 · DOI 10.1007/s40263-019-00613-7
Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?
Dong Y, Li X, Cheng J, Hou L. · · 2019 · cited 97× · PMID 30696107 · DOI 10.3390/ijms20030558
Alzheimer's drug-development pipeline: 2016.
Cummings J, Morstorf T, Lee G. · · 2016 · cited 78× · PMID 29067309 · DOI 10.1016/j.trci.2016.07.001

Verify or expand the search:

Other trials of E2609

Trials testing the same drug.

NCT03055962 — Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects · Phase 1 · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02322021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 5 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02322021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02322021

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (24 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of E2609

Other recruiting trials for Alzheimer Disease

Other Eisai Inc. trials

Verify against primary sources